6533b7dafe1ef96bd126f595
RESEARCH PRODUCT
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.
Bruno VincenziEvaristo MaielloCristina MasiniOlga VendittiRaffaele AddeoAlfredo FalconeVincenzo CatalanoVladimir VirzìCinzia OrtegaR. GiannicolaN. CalipariToni IbrahimGiuseppe ToniniPaolo GiordaniCalogero MazzaraAzzurra OttoneFausto PetrelliStefano CascinuNicola SilvestrisFederica BertoliniDaniele SantiniLisa SalvatoreSandro BarniTiziana LatianoMaria Elisabetta FrattoMarco TampelliniCinzia CarotiRossana BerardiMassimo AgliettaGiuseppe BadalamentiDavide OttavianiFrancesco Fabbrisubject
Oncologymedicine.medical_specialtyBone Density Conservation AgentSettore MED/06 - Oncologia MedicaColorectal cancerBone NeoplasmsColorectal NeoplasmBone Neoplasmdrug therapy/pathologyZoledronic AcidInternal medicinemedicineHumansImidazolePelvisRetrospective Studiesdrug therapy/secondarybone metastases colorectal cancer zoledronic acidBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesBone metastasisCancerRetrospective cohort studyHematologymedicine.diseaseNatural historyBone Density Conservation AgentsZoledronic acidmedicine.anatomical_structureDiphosphonateOncologytherapeutic useBone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy/secondary; Colorectal Neoplasms; drug therapy/pathology; Diphosphonates; Humans; Imidazoles; Retrospective StudiesbusinessColorectal NeoplasmsHumanmedicine.drugdescription
ABSTRACT Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to bone metastases was 11.00 months; median time to first SRE thereafter was 2.00 months. Radiation and pathologic fractures affected 45% and 10% of patients, respectively; 32% of patients had no reported SREs. Patients survived for a median of 7.00 months after bone metastases diagnosis; SREs did not significantly affect survival. Subgroup analyses revealed that zoledronic acid significantly prolonged median time to first SRE (2.00 months versus 1.00 month, respectively, P = 0.009) and produced a trend toward improved overall survival versus no zoledronic acid. Conclusion This study illustrates the burden of bone metastases from CRC and supports the use of zoledronic acid in this setting.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2012-01-01 |